Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome

Basit Öğe Kaydı
dc.authoridTürköz, Yusuf/0000-0001-5401-0720;
dc.authorwosidTürköz, Yusuf/ABG-7931-2020
dc.authorwosidcekmen, mustafa baki/G-6122-2011
dc.authorwosidÖzerol, İbrahim Halil/ABI-8015-2020
dc.authorwosidEvereklioğlu, Cem/A-5370-2018
dc.contributor.authorÇekmen, M
dc.contributor.authorEvereklioglu, C
dc.contributor.authorEr, H
dc.contributor.authorInalöz, HS
dc.contributor.authorDoganay, S
dc.contributor.authorTürköz, Y
dc.contributor.authorÖzerol, IH
dc.date.accessioned2024-08-04T20:13:33Z
dc.date.available2024-08-04T20:13:33Z
dc.date.issued2003
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/aims Vascular endothelial growth factor (VEGF) is a cytokine participating in inflammation with potent endothelial cell effects. It is produced by macrophages, neutrophils and vascular endothelial cells and can alter vessel permeability. Behcet's syndrome is a systemic inflammatory disorder with unknown etiology. Vascular endothelial dysfunction is one of the prominent features of the disease. We previously demonstrated the possible involvement of proinflammatory cytokines [tumor necrosis factor (TNF)-alpha, soluble interleukin-2 receptor (sIL-2R), interleukin (IL)-6 and IL-8], nitric oxide (NO) and adrenomedullin in the etiopathogenesis of Behcet's syndrome. Since VEGF expression is induced by these cytokines and VEGF itself is a potent stimulator of NO production with endothelial cell effects, this study aimed to investigate whether VEGF was affected during the course of Behcet's syndrome. We also assessed the possible involvement of VEGF in ocular Behcet's syndrome or in disease activity. Methods This multicenter case-control study included a total of 39 patients with active (n = 22) or inactive (n = 17) Behcet's syndrome (mean age, 38.1 +/- 10.4 years; 21 men and 18 women) satisfying International Study Group criteria, and 15 healthy hospital-based control volunteers (mean age, 39.2 +/- 9.3 years; eight men and seven women) matched for age and gender from a similar ethnic background. Patients were examined by a dermatologist and an ophthalmologist with an interest in Behcet's syndrome. Plasma VEGF concentrations were measured using a newly established enzyme-linked immunosorbent assay. Clinical findings and acute-phase reactant parameters such as erythrocyte sedimentation rate, alpha(1)-antitrypsin, alpha(2)-macroglobulin, and neutrophil count were used to classify the disease in Behcet's patients as active or inactive. The Wilcoxon test or the Mann-Whitney U-test was used for statistical analysis as indicated and the results were expressed as mean +/- SD, with range. Results The mean plasma VEGF level in patients with Behcet's syndrome (291.9 +/- 97.1 pg/mL; range 121-532 pg/mL) was higher than that in control subjects (103.0 +/- 43.6 pg/mL; range 25-187 pg/mL) and the difference was significant (P < 0.001). Patients with active disease had significantly (P < 0.001) higher VEGF levels than patients with inactive disease (347.6 +/- 87.1 vs. 219.9 +/- 51.6 pg/mL). In addition, ocular Behcet's patients (n = 23) had higher VEGF levels (315.7 +/- 92.1 pg/mL) than nonocular patients (n = 16, 257.8 +/- 96.6 pg/mL) and the difference was of borderline significance (P = 0.041). The levels of all acute-phase reactant parameters were significantly higher in the active stage than in the inactive stage (for each, P < 0.01) or in control subjects (for each, P < 0.001). Conclusions VEGF may participate in the course of Behcet's syndrome, especially in the active stage, and elevated levels of VEGF may be an additional risk factor for the development of ocular disease, contributing to poor visual outcome.en_US
dc.identifier.doi10.1046/j.1365-4362.2003.01688.x
dc.identifier.endpage875en_US
dc.identifier.issn0011-9059
dc.identifier.issn1365-4632
dc.identifier.issue11en_US
dc.identifier.pmid14636202en_US
dc.identifier.scopus2-s2.0-0345307607en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage870en_US
dc.identifier.urihttps://doi.org/10.1046/j.1365-4362.2003.01688.x
dc.identifier.urihttps://hdl.handle.net/11616/93693
dc.identifier.volume42en_US
dc.identifier.wosWOS:000186171200002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNitric-Oxideen_US
dc.subjectPermeability Factoren_US
dc.subjectAdrenomedullin Levelsen_US
dc.subjectFactor Vegfen_US
dc.subjectTnf-Alphaen_US
dc.subjectCellsen_US
dc.subjectExpressionen_US
dc.subjectDysfunctionen_US
dc.subjectHypoxiaen_US
dc.subjectInvolvementen_US
dc.titleVascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu